Effectiveness and Safety of Therapeutic Vaccines for Precancerous Cervical Lesions: A Systematic Review and Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 23

PMID 35734598

Authors

Shan Cai

Xiaoyu Tan

Ke Miao

Dantong Li

Si Cheng

Pei Li

Xueyang Zeng

Feng Sun

Affiliations

Soon will be listed here.

Abstract

Objective: This study systematically evaluated the effectiveness and safety of therapeutic vaccines for precancerous cervical lesions, providing evidence for future research.

Methods: We systematically searched the literature in 10 databases from inception to February 18, 2021. Studies on the effectiveness and safety of therapeutic vaccines for precancerous cervical lesions were included. Then, we calculated the overall incidence rates of four outcomes, for which we used the risk ratio (RR) and 95% confidence interval (95% CI) to describe the effects of high-grade squamous intraepithelial lesions (HSILs) on recurrence.

Results: A total of 39 studies were included, all reported in English, published from 1989 to 2021 in 16 countries. The studies covered 22,865 women aged 15-65 years, with a total of 5,794 vaccinated, and 21 vaccines were divided into six types. Meta-analysis showed that the overall incidence rate of HSIL regression in vaccine therapies was 62.48% [95% CI (42.80, 80.41)], with the highest rate being 72.32% for viral vector vaccines [95% CI (29.33, 99.51)]. Similarly, the overall incidence rates of HPV and HPV16/18 clearance by vaccines were 48.59% [95% CI (32.68, 64.64)] and 47.37% [95% CI (38.00, 56.81)], respectively, with the highest rates being 68.18% [95% CI (45.13, 86.14)] for bacterial vector vaccines and 55.14% [95% CI (42.31, 67.66)] for DNA-based vaccines. In addition, a comprehensive analysis indicated that virus-like particle vaccines after conization reduced the risk of HSIL recurrence with statistical significance compared to conization alone [RR = 0.46; 95% CI (0.29, 0.74)]. Regarding safety, only four studies reported a few severe adverse events, indicating that vaccines for precancerous cervical lesions are generally safe.

Conclusion: Virus-like particle vaccines as an adjuvant immunotherapy for conization can significantly reduce the risk of HSIL recurrence. Most therapeutic vaccines have direct therapeutic effects on precancerous lesions, and the effectiveness in HSIL regression, clearance of HPV, and clearance of HPV16/18 is great with good safety. That is, therapeutic vaccines have good development potential and are worthy of further research.

Systematic Review Registration: PROSPERO https://www.crd.york.ac.uk/PROSPERO/, CRD42021275452.

Citing Articles

Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials.

Ibrahim Khalil A, Zhang L, Muwonge R, Sauvaget C, Basu P BMJ Open. 2023; 13(10):e069616.

PMID: 37879679 PMC: 10603536. DOI: 10.1136/bmjopen-2022-069616.

Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression.

Petras M, Dvorak V, Lomozova D, Macalik R, Neradova S, Dlouhy P Sex Transm Infect. 2023; 99(8):561-570.

PMID: 37553234 PMC: 10715477. DOI: 10.1136/sextrans-2023-055793.

References

Park Y, Ouh Y, Sung M, Park H, Kim T, Cho C . A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3. J Gynecol Oncol. 2019; 30(6):e88. PMC: 6779607. DOI: 10.3802/jgo.2019.30.e88. View

Garcia-Hernandez E, Gonzalez-Sanchez J, Andrade-Manzano A, Contreras M, Padilla S, Guzman C . Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther. 2006; 13(6):592-7. DOI: 10.1038/sj.cgt.7700937. View

Del Pino M, Marti C, Torras I, Henere C, Munmany M, Marimon L . HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions. Vaccines (Basel). 2020; 8(2). PMC: 7349984. DOI: 10.3390/vaccines8020245. View

Solares A, Baladron I, Ramos T, Valenzuela C, Borbon Z, Fanjull S . Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011:292951. PMC: 3118643. DOI: 10.5402/2011/292951. View

Jentschke M, Kampers J, Becker J, Sibbertsen P, Hillemanns P . Prophylactic HPV vaccination after conization: A systematic review and meta-analysis. Vaccine. 2020; 38(41):6402-6409. DOI: 10.1016/j.vaccine.2020.07.055. View

Alvarez R, Huh W, Bae S, Lamb Jr L, Conner M, Boyer J . A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol. 2015; 140(2):245-52. PMC: 4724445. DOI: 10.1016/j.ygyno.2015.11.026. View

Greenfield W, Stratton S, Myrick R, Vaughn R, Donnalley L, Coleman H . A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology. 2015; 4(10):e1031439. PMC: 4590015. DOI: 10.1080/2162402X.2015.1031439. View

Trimble C, Morrow M, Kraynyak K, Shen X, Dallas M, Yan J . Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b.... Lancet. 2015; 386(10008):2078-2088. PMC: 4888059. DOI: 10.1016/S0140-6736(15)00239-1. View

Harper D, Nieminen P, Donders G, Einstein M, Garcia F, Huh W . The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. Gynecol Oncol. 2019; 153(3):521-529. DOI: 10.1016/j.ygyno.2019.03.250. View

10.

Komdeur F, Singh A, van de Wall S, Meulenberg J, Boerma A, Hoogeboom B . First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers. Mol Ther. 2020; 29(2):611-625. PMC: 7854293. DOI: 10.1016/j.ymthe.2020.11.002. View

11.

Brun J, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf J . Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol. 2011; 204(2):169.e1-8. DOI: 10.1016/j.ajog.2010.09.020. View

12.

Balajewicz M, Dembowska J, KLIMEK R . Test of immunopotentialization in colposcopy--a clinical evaluation. Eur J Obstet Gynecol Reprod Biol. 1989; 33(3):253-7. DOI: 10.1016/0028-2243(89)90138-x. View

13.

Dalziel K, Round A, Stein K, Garside R, Castelnuovo E, Payne L . Do the findings of case series studies vary significantly according to methodological characteristics?. Health Technol Assess. 2004; 9(2):iii-iv, 1-146. DOI: 10.3310/hta9020. View

14.

Trimble C, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E . A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009; 15(1):361-7. PMC: 2865676. DOI: 10.1158/1078-0432.CCR-08-1725. View

15.

Roman L, Wilczynski S, Muderspach L, Burnett A, OMeara A, Brinkman J . A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2007; 106(3):558-66. DOI: 10.1016/j.ygyno.2007.05.038. View

16.

Sand F, Kjaer S, Frederiksen K, Dehlendorff C . Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer. 2019; 147(3):641-647. DOI: 10.1002/ijc.32752. View

17.

Kawana K, Adachi K, Kojima S, Taguchi A, Tomio K, Yamashita A . Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. Vaccine. 2014; 32(47):6233-9. DOI: 10.1016/j.vaccine.2014.09.020. View

18.

Bagarazzi M, Yan J, Morrow M, Shen X, Parker R, Lee J . Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012; 4(155):155ra138. PMC: 4317299. DOI: 10.1126/scitranslmed.3004414. View

19.

Kalliala I, Athanasiou A, Veroniki A, Salanti G, Efthimiou O, Raftis N . Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol. 2020; 31(2):213-227. PMC: 7479506. DOI: 10.1016/j.annonc.2019.11.004. View

20.

Kaufmann A, Nieland J, Jochmus I, Baur S, Friese K, Gabelsberger J . Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer. 2007; 121(12):2794-800. DOI: 10.1002/ijc.23022. View